AI Article Synopsis
- Primary skull base osteosarcoma is a very rare type of cancer, mostly seen in people during their teenage years.
- There have been two documented cases of this cancer originating from the anterior cranial fossa, which is located at the front of the skull.
- Surprisingly, both patients with these rare cases were in their 50s, differing from the typical age group for this disease.
Article Abstract
Primary skull base osteosarcoma is extremely rare and has been reported mainly in the second decade of life. Two cases of primary osteosarcoma arising from the anterior cranial fossa have been described. Both these patients were in their fifth decades of life.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Primary extraskeletal osteosarcoma of rectal mesentery: a rare case and literature review.
World J Surg Oncol
January 2025
The Department of General Surgery, The Second Hospital of Jilin University, Changchun, 130041, China.
Background: Extraskeletal osteosarcoma (ESOS) is a rare kind of sarcoma with a low preoperative diagnosis and a poor prognosis. ESOS arising from abdominal mesentery is extremely rare. Increasing diagnostic methods and standardizing treatment protocols are crucial issues of ESOS.
View Article and Find Full Text PDFA detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration.
BJC Rep
January 2025
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background: Osteosarcoma is the most common malignant bone tumour with limited treatment options and poor outcomes in advanced metastatic cases. Current immunotherapies show limited efficacy, highlighting the need for novel therapeutic approaches. Systemic immune activation by Toll-like receptor 4 (TLR4) immunostimulants has shown great promise; however, current TLR4 agonists' toxicity hinders this systemic approach in patients with osteosarcoma.
View Article and Find Full Text PDFHistological Type-Specific Behavior in Sarcomas: Analysis of Head and Neck Cancer Registry of Japan.
Laryngoscope
January 2025
Department of Otolaryngology, Head and Neck Surgery, The University of Tokyo, Tokyo, Japan.
Objective: The goal of this study was to better understand the epidemiology, clinical characteristics, and treatment outcomes of head and neck sarcomas using real-world data from Japan.
Methods: Using the Japanese Head and Neck Cancer Registry, we identified 438 patients who were pathologically diagnosed with head and neck sarcoma between 2011 and 2020. We compared epidemiological, clinical, and prognostic data for the different histological types of sarcoma.
iRGD-Targeted Biosynthetic Nanobubbles for Ultrasound Molecular Imaging of Osteosarcoma.
Int J Nanomedicine
January 2025
Department of Ultrasound, The second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518061, People's Republic of China.
Purpose: Osteosarcoma is the most common primary malignant tumor of the bone. However, there is a lack of effective means for early diagnosis due to the heterogeneity of tumors and the complexity of tumor microenvironment. αvβ3 integrin, a crucial role in the growth and spread of tumors, is not only an effective biomarker for cancer angiogenesis, but also highly expressed in many tumor cells.
View Article and Find Full Text PDFMandibular ossifying fibroma in 2 cattle in Brazil.
J Vet Diagn Invest
January 2025
Veterinary Pathology Laboratory, Veterinary Hospital-Universidade Federal de Mato Grosso, Cuiabá, Brazil.
Ossifying fibroma (OF) is a slow-growing, expansive, and benign fibro-osseous neoplasm that is rare in cattle. It mainly affects the craniofacial bones, especially the mandible. Here, we report 2 cases of mandibular OF in Nelore and mixed-breed steers with enlarged masses in the rostral portion of the mandible.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!